A Study to Determine the Efficacy and Safety of Cabergoline for the Treatment of Patients With RLS

Back to Search
Print
Bookmark Trial

NCT00625547

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Innsbruck, , 6020, Austria
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Restless Legs Syndrome
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-75 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Diagnosis of idiopathic RLS and had all 4 clinical manifestations of RLS

- Moderate to severe symptoms of RLS as indicated by an IRLSSG-RS total score greater than or equal to 10 and a severity at night score of greater than or equal to 4 on an 11-point RLS-6 rating scale

- No previous treatment for RLS or dissatisfaction with their current therapy

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Not available

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Restless Legs SyndromeA Study to Determine the Efficacy and Safety of Cabergoline for the Treatment of Patients With RLS
NCT00625547
  1. Innsbruck,
  2. Wien,
  3. Altoetting,
  4. Aschaffenburg,
  5. Bad Honnef,
  6. Bad Saarow,
  7. Beckum,
  8. Berlin,
  9. Berlin,
  10. Berlin,
  11. Berlin,
  12. Berlin,
  13. Bochum,
  14. Bremerhaven,
  15. Dillingen,
  16. Duesseldorf,
  17. Duisburg,
  18. Gelsenkirchen,
  19. Gera,
  20. Goettingen,
  21. Goettingen,
  22. Halle,
  23. Hamburg,
  24. Heilbronn,
  25. Jena,
  26. Kaiserslautern,
  27. Karlsruhe,
  28. Karlsruhe,
  29. Kassel,
  30. Köthen,
  31. Marburg,
  32. Mittweida,
  33. Moenchengladbach,
  34. Neubrandenburg,
  35. Oldenburg,
  36. Quickborn,
  37. Regensburg,
  38. Schwalmstadt,
  39. Schwerin,
  40. Stuttgart,
  41. Tuttlingen,
  42. Ulm,
  43. Wiesbaden,
  44. Wolfsburg,
  45. Goteborg,
  46. Karlstad,
  47. Linköping,
  48. Basel,
  49. Bern,
  50. Zürich,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Restless Legs SyndromeLyrica Dose Response Study With Restless Legs Syndrome (RLS) Patients
NCT00676403
  1. Tuscaloosa, Alabama
  2. Little Rock, Arkansas
  3. San Diego, California
  4. Santa Monica, California
  5. Aurora, Colorado
  6. Brandon, Florida
  7. Macon, Georgia
  8. Louisville, Kentucky
  9. Baton Rouge, Louisiana
  10. Raleigh, North Carolina
  11. Salisbury, North Carolina
  12. Winston-Salem, North Carolina
  13. Oklahoma City, Oklahoma
  14. Dallas, Texas
  15. Alexandria, Virginia
  16. Innsbruck,
  17. Vienna,
  18. Bad Saarow,
  19. Berlin,
  20. Goettingen,
  21. Mittweida,
  22. Muenchen,
  23. Oldenburg,
  24. Schwerin,
  25. Madrid,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Restless Legs SyndromeA Study to Evaluate the Efficacy and Safety of Cabergoline Compared With Placebo for the Treatment of RLS
NCT00627003
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Restless Legs SyndromePolysomnography Study Of Pregabalin And Pramipexole Versus Placebo In Patients With Restless Legs Syndrome And Associated Sleep Disturbance
NCT00991276
  1. Jasper, Alabama
  2. Phoenix, Arizona
  3. Tucson, Arizona
  4. Little Rock, Arkansas
  5. Little Rock, Arkansas
  6. Burlingame, California
  7. Pasadena, California
  8. Redlands, California
  9. San Diego, California
  10. San Diego, California
  11. Santa Ana, California
  12. Santa Monica, California
  13. Aurora, Colorado
  14. Hallandale Beach, Florida
  15. Miami, Florida
  16. Pembroke Pines, Florida
  17. Spring Hill, Florida
  18. Atlanta, Georgia
  19. Macon, Georgia
  20. Overland Park, Kansas
  21. Crestview Hills, Kentucky
  22. Lexington, Kentucky
  23. Baton Rouge, Louisiana
  24. Chevy Chase, Maryland
  25. Brighton, Massachusetts
  26. Kalamazoo, Michigan
  27. Portage, Michigan
  28. New York, New York
  29. Hickory, North Carolina
  30. Raleigh, North Carolina
  31. Winston Salem, North Carolina
  32. Winston-Salem, North Carolina
  33. Cincinnati, Ohio
  34. Dublin, Ohio
  35. Middleburg Heights, Ohio
  36. Oklahoma City, Oklahoma
  37. Clarks Summit, Pennsylvania
  38. Lafayette Hill, Pennsylvania
  39. Columbia, South Carolina
  40. Austin, Texas
  41. Austin, Texas
  42. Dallas, Texas
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Study to Determine the Efficacy and Safety of Cabergoline for the Treatment of Patients With RLS
Official Title  ICMJE A Double-Blind, Randomized, Active-Controlled Multicenter Efficacy Trial for the Treatment of Patients With Restless Legs Syndrome (RLS)
Brief Summary The purpose of this study is to evaluate the efficacy and safety of cabergoline compared with levodopa in the treatment of patients with RLS.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Condition  ICMJE Restless Legs Syndrome
Intervention  ICMJE
  • Drug: cabergoline
    Cabergoline oral tablets: 0.5 mg daily on Days 1 to 3, 1.0 mg daily on Days 4 to 7, 1.5 mg daily on Days 8 to 10, and 2.0 mg daily on Days 11 to 14 and then administered as a stable dose for a further 4 weeks; at Week 6, dose could be increased to 3 mg daily if patient experienced insufficient efficacy without impairing adverse events
  • Drug: levodopa
    Levodopa oral capsules: 25 mg twice daily on Days 1 to 3, 50 mg twice daily on Days 4 to 7, 100 mg twice daily on Days 8 to 14 and then administered as a stable dose for a further 4 weeks; at Week 6, dose could be increased to 150 mg twice daily if patient experienced insufficient efficacy without impairing adverse events
Study Arms  ICMJE
  • Experimental: 1
    Intervention: Drug: cabergoline
  • Experimental: 2
    Intervention: Drug: levodopa
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: October 28, 2008)		361
Original Actual Enrollment  ICMJE
 (submitted: February 27, 2008)		340
Actual Study Completion Date  ICMJE December 2004
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Diagnosis of idiopathic RLS and had all 4 clinical manifestations of RLS
  • Moderate to severe symptoms of RLS as indicated by an IRLSSG-RS total score greater than or equal to 10 and a severity at night score of greater than or equal to 4 on an 11-point RLS-6 rating scale
  • No previous treatment for RLS or dissatisfaction with their current therapy

Exclusion Criteria:

  • Not available
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Austria,   Germany,   Sweden,   Switzerland
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00625547
Other Study ID Numbers  ICMJE CABAS-0067-031
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date October 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP